Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B

por Mahlangu, Johnny, Levy, Howard, Lee, Martin, Del Greco, Frank
Publicado 2021

Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety

por Mahlangu, Johnny, Levy, Howard, Kosinova, Marina V., Khachatryan, Heghine, Korczowski, Bartosz, Makhaldiani, Levani, Iosava, Genadi, Lee, Martin, Del Greco, Frank
Publicado 2021